¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"essential hypertension"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • essential thrombocytopenia
    º»ÅÂÇ÷¼ÒÆÇ°¨¼Ò(Áõ)
  • essential tremor
    º»Å¶³¸²
  • essential vertigo
    º»ÅÂÇö±âÁõ
  • minimum essential medium
    ÃÖ¼ÒÇʼö¿µ¾ç¹èÁö
  • accelerated hypertension
    °¡¼Ó°íÇ÷¾Ð
  • adrenal hypertension
    ºÎ½Å¼º°íÇ÷¾Ð
  • borderline hypertension
    °æ°è°íÇ÷¾Ð
  • diastolic hypertension
    È®Àå±â°íÇ÷¾Ð
  • hypertension
    1. °íÇ÷¾Ð 2. °íÇ÷¾ÐÁõ 3. °í¾Ð
  • intracranial hypertension
    µÎ°³³»¾Ð»ó½Â
  • juvenile hypertension
    ¼Ò¾Æ°íÇ÷¾Ð
  • labile hypertension
    ºÒ¾ÈÁ¤°íÇ÷¾Ð
  • low renin hypertension
    Àú·¹´Ñ°íÇ÷¾Ð
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾Ð
  • ocular hypertension
    °í¾È¾Ð
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • essential telangiectasia
    º»Å¸ð¼¼Ç÷°üÈ®ÀåÁõ,
  • essential tremor
    º»Å¶³¸², À¯Àü¶³¸², ¿øÀθ𸦶³¸²
  • essential vertigo
    ¿øÀκҸí¾îÁö·³, º»ÅÂÇö±âÁõ
  • essential melanotic mucosal hyperplasia
    º»ÅÂÁ¡¸·¸á¶ó´ÑÁ¡¸·Áõ½Ä
  • minimum essential medium
    ÃÖ¼ÒÇʼö¿µ¾ç¹èÁö
  • accelerated hypertension
    °¡¼Ó°íÇ÷¾Ð
  • adrenal hypertension
    ºÎ½Å°íÇ÷¾Ð
  • borderline hypertension
    °æ°è°íÇ÷¾Ð
  • diastolic hypertension
    È®Àå±â°íÇ÷¾Ð
  • hypertension
    °íÇ÷¾Ð
  • intracranial hypertension
    µÎ°³³»¾Ð»ó½Â
  • juvenile hypertension
    ¼Ò¾Æ°íÇ÷¾Ð
  • labile hypertension
    (¢¡borderline hypertension) °æ°è°íÇ÷¾Ð
  • low renin hypertension
    Àú·¹´Ñ°íÇ÷¾Ð
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾Ð
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • portal hypertension
    ¹®¸Æ¾ÐÇ×ÁøÁõ(Ú¦Øæäâùñòäñø), ¹®¸Æ°íÇ÷¾Ð(Ú¦ØæÍÔúìäâ)
  • portal hypertension
    ¹®¸Æ¾ÐÇ×ÁøÁõ
  • primary hypertension
    ¿ø¹ß(¼º) °íÇ÷¾ÐÁõ (¡­ÍÔúìäâñø).
  • primary hypertension
    ¿ø¹ß(¼º) °íÇ÷¾ÐÁõ(ê«Û¡(àõ) ÍÔúìäâñø)
  • primary pulmonary hypertension
    ¿ø¹ß(¼º) Æó°íÇ÷¾ÐÁõ(¡­øËÍÔúìäâñø).
  • primary pulmonary hypertension
    ¿ø¹ß(¼º) Æó°íÇ÷¾ÐÁõ(ê«Û¡(àõ) øËÍÔúìäâñø)
  • pulmonary hypertension
    Æóµ¿¸Æ°íÇ÷¾Ð, Æó°íÇ÷¾ÐÁõ.
  • pulmonary hypertension
    Æóµ¿¸Æ°íÇ÷¾Ð(øËÔÑØæÍÔúìäâ), Æó°íÇ÷¾ÐÁõ(øËÍÔúìäâñø)
  • red hypertension
    È«Á¶¼º °íÇ÷¾ÐÁõ(ûõðÍàõÍÔúìäâñø).
  • red hypertension
    È«Á¶¼º °íÇ÷¾ÐÁõ(ûõðÍàõÍÔúìäâñø)
  • renal hypertension
    ½Å¼º °íÇ÷¾Ð(ãìàõÍÔúìäâ).
  • renal hypertension
    ½Å¼º °íÇ÷¾Ð(¡­ÍÔúìäâ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intracranial hypertension
    µÎ°³³»°íÇ÷¾Ð (¡­ÍÔúìäâ).
  • juvenile hypertension
    ¿¬¼Ò¼º °íÇ÷¾Ð(Áõ).
  • kallikrein-kinin,renal hypertension
    ½Å¼º°íÇ÷¾Ð(½Å¼º ÍÔúìäâ)
  • labile hypertension
    ºÒ¾ÈÁ¤¼º °íÇ÷¾Ð (¡­ÍÔúìäâ).
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾ÐÁõ(ÊÙË­Ì´ËâÌ¡).
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾ÐÁõ(¡­ÍÔúìäâñø).
  • nephrogenous hypertension
    ½Å¼º°íÇ÷¾Ð (~ÍÔúìäâ).
  • ocular hypertension
    °í¾È¾ÐÁõ
  • ocular hypertension indicator =OHI
    ¾È±¸°íÇ÷¾ÐÁöÇ¥(äÑϹÍÔúìäâò¦øö).
  • orthostatic hypertension
    ±â¸³¼º °íÇ÷¾Ð.
  • portal hypertension
    ¹®¸Æ¾ÐÇ×ÁøÁõ(Ú¦Øæäâùñòäñø), ¹®¸Æ°íÇ÷¾Ð(¡­ÍÔúìäâ).
  • portal hypertension
    ¹®¸Æ¾ÐÇ×ÁøÁõ(Ú¦Øæäâùñòäñø), ¹®¸Æ°íÇ÷¾Ð(Ú¦ØæÍÔúìäâ)
  • portal hypertension
    ¹®¸Æ¾ÐÇ×ÁøÁõ
  • primary hypertension
    ¿ø¹ß(¼º) °íÇ÷¾ÐÁõ (¡­ÍÔúìäâñø).
  • primary hypertension
    ¿ø¹ß(¼º) °íÇ÷¾ÐÁõ(ê«Û¡(àõ) ÍÔúìäâñø)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NREH normal renin essential hypertension
REH renin essential hypertension
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
IPH idiopathic portal hypertension; idiopathic pulmonary hemosiderosis; idiopathic pulmonary hypertensio...
PHT phenytoin; portal hypertension; primary hyperthyroidism; pulmonary hypertension
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EFA Essential Fatty Acid
EFAD Essential Fatty Acid Deficient
EMC Essential Mixed Cryoglobulinemia
ET Essential Thrombocythemia
ET Essential Tremor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • primary hypertension
    ¿ø¹ß °íÇ÷¾ÐÁõ, ¿ø¹ß¼º °íÇ÷¾ÐÁõ
  • pulmonary arterial hypertension
    Æó ¼øÈ¯ ½Â¾Ð
  • pulmonary hypertension
    Æó ¼øÈ¯ ½Â¾Ð, Æó °íÇ÷¾ÐÁõ
  • renal hypertension
    ½Å¼º °íÇ÷¾Ð
  • splenoportal hypertension
    ºñ ¹®¸Æ¼º °íÇ÷¾ÐÁõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
essential gene <genetics> Any gene that, if it does not workcorrectly, kills the organism.
(09 Oct 1997)
essential oils Plant products, usually somewhat volatile, giving the odours and tastes characteristic of the particular plant, thus possessing the essence, e.g., citral, pinene, camphor, menthane, terpenes; usually, the steam distillates of plants or oils of plants obtained by pressing out the rinds of a particular plant.
See: volatile oil.
(05 Mar 2000)
essential phthisis bulbi A softening of the eyeball (ophthalmomalacia) and reduction in size, not due to inflammation.
(05 Mar 2000)
essential progressive atrophy of iris Progressive atrophy of the iris without inflammatory signs, characterised by patchy loss of all layers of the iris with hole formation, migration of the pupil, degeneration of the corneal endothelium, peripheral anterior synechiae, and secondary glaucoma; usually unilateral, predominantly affecting women in their middle years.
(05 Mar 2000)
essential pruritus Itching that occurs independently of skin lesions.
(05 Mar 2000)
essential tachycardia Persistent rapid action of the heart due to no discoverable organic lesion.
(05 Mar 2000)
essential telangiectasia Localised capillary dilation of undetermined origin.
Synonym: angioma serpiginosum.
(05 Mar 2000)
essential thrombocythaemia A rare condition related to polycythaemia rubra vera characterised by the production of large numbers of abnormal platelets.
Symptoms include haemorrhage, blood clots and enlargement of the spleen. Treatment varies according to the severity of the disease.
(13 Nov 1997)
essential thrombocytopenia A primary form of thrombocytopenia, in contrast to secondary forms that are associated with metastatic neoplasms, tuberculosis, and leukaemia involving the bone marrow, or with direct suppression of bone marrow by the use of chemical agents, or with other conditions.
(05 Mar 2000)
essential tremor <neurology> A tremor that is associated with purposeful movement or motor activity. Essential tremor is the most common form of tremor with no identifiable cause. Stress, anxiety and the use of stimulants (for example caffeine, decongestants) can often make the tremor worse. Treatment is usually not necessary for this benign condition.
(27 Sep 1997)
fatty acids, essential Fatty acids that cannot be synthesised by the human body and must be obtained from dietary sources, e.g., linoleic acids and linolenic acids.
(12 Dec 1998)
accelerated hypertension <cardiology> A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure.
Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension.
(27 Sep 1997)
adrenal hypertension Hypertension due to an adrenal medullary pheochromocytoma or to hyperactivity or functioning tumour of the adrenal cortex.
(05 Mar 2000)
benign hypertension Hypertension that runs a relatively long and symptomless course.
(05 Mar 2000)
borderline hypertension By consensus, that blood pressure zone between highest acceptable "normal" blood pressure and hypertensive blood pressure. The Framingham Heart Study defines this as pressures between 140 and 160 mm Hg systolic and 90 and 95 mm Hg diastolic.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á